Study guide

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support

Certified Burn Registered Nurse CBRN

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Foundations of Burn Care

1.1 CBRN Exam Format, Eligibility, and BCEN Testing Standards 1.2 Anatomy, Histology, and Barrier Functions of the Skin 1.3 Burn Depth Classification and Jackson's Thermal Wound Zones

2 Chapter 2: Pathophysiology of Burn Injury & Systemic Response

2.1 Cellular Pathophysiology and Capillary Permeability in Burn Shock 2.2 Systemic Inflammatory Response Syndrome (SIRS) and MODS 2.3 Pathophysiology of Supraglottic, Subglottic, and Inhalational Injury 2.4 Cellular Phases of Burn Wound Healing and Scar Pathobiology

3 Chapter 3: Prehospital Triage, Primary Survey & Transfer Criteria

3.1 Initial Assessment, Primary Survey (ABCDEF), and Field Stabilization 3.2 Total Body Surface Area (TBSA) Calculation: Rule of Nines, Lund-Browder, and Palmar Method 3.3 American Burn Association (ABA) Burn Center Referral Criteria and Transport Logistics

4 Chapter 4: Fluid Resuscitation & Hemodynamic Stabilization (<72 Hours)

4.1 Fluid Resuscitation Formulas: Parkland (Baxter), Modified Brooke, and Consensus Protocols 4.2 Resuscitation Endpoints: Urine Output Titration, Base Deficit, and Hemodynamic Monitoring 4.3 Complications of Fluid Creep and Intra-Abdominal Hypertension / Abdominal Compartment Syndrome 4.4 Extremity Compartment Syndrome, Monitoring, and Emergent Escharotomy / Fasciotomy

5 Chapter 5: Airway Management & Inhalation Injury Management

5.1 Upper Airway Compromise, Indications for Early Endotracheal Intubation, and Airway Stabilization 5.2 Lower Airway Chemical Tracheobronchitis, Diagnostic Bronchoscopy, and Lung-Protective Mechanical Ventilation 5.3 Carbon Monoxide (CO) Toxicity, Cyanide Poisoning, and Specific Antidotes (Hydroxocobalamin)

6 Chapter 6: Acute Multisystem Assessment & Critical Care Management

6.1 Cardiovascular Derangements, Myocardial Depression, and Hemodynamic Optimization 6.2 Acute Kidney Injury, Rhabdomyolysis / Myoglobinuria, and Fluid-Electrolyte Shifts 6.3 Gastrointestinal Complications, Ileus, Early Enteral Nutrition, and Curling's Ulcer Prophylaxis 6.4 Neurological Impairment, Anemia of Burn Injury, Coagulopathy, and Musculoskeletal Protection

7 Chapter 7: Hypermetabolism & Nutritional Support

7.1 The Biphasic Metabolic Response: Ebb vs. Flow Phases and Persistent Hypermetabolism 7.2 Indirect Calorimetry, Caloric Equations (Curreri/Toronto), and Micronutrient / Trace Mineral Needs 7.3 Pharmacological Modulation: Propranolol, Oxandrolone, Growth Hormone, and Exercise Therapy 7.4 Stress Hyperglycemia, Intensive Insulin Protocols, and Adrenal / Thyroid Axis Dysregulation

8 Chapter 8: Pain Management in Burn Care

8.1 Pain Classification in Burns: Background, Procedural, Breakthrough, and Chronic Neuropathic Pain 8.2 Multimodal Analgesia: Opioids, Ketamine, Gabapentinoids, NSAIDs, and Regional Anesthesia 8.3 Non-Pharmacological Modalities: Virtual Reality, Cognitive Behavioral Techniques, Hypnosis, and Distraction

9 Chapter 9: Agitation, Delirium & Post-Burn Pruritus

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support 9.2 ICU Delirium: Risk Factors, Screening (CAM-ICU/ICDSC), Non-Pharmacological Bundles, and Medical Management 9.3 Post-Burn Itch: Histaminergic vs. Neuropathic Pruritus, Oral Antihistamines, Gabapentin, and Topical Emollients

10 Chapter 10: Burn Wound Assessment, Topical Antimicrobials & Dressings

10.1 Serial Wound Bed Assessment, Tissue Perfusion, and Documentation Standards 10.2 Topical Antimicrobial Formulations: Silver Sulfadiazine, Mafenide Acetate, Silver Nitrate, and Modern Silver Dressings 10.3 Wound Bed Preparation: Surgical, Enzymatic (Collagenase/Bromelain), Autolytic, and Mechanical Debridement 10.4 Modern Dressings, Hydrogels, Foam Dressings, Negative Pressure Wound Therapy (NPWT), and Moisture Retentive Balances

11 Chapter 11: Surgical Excision, Skin Grafting & Wound Closure

11.1 Principles of Early Tangential vs. Fascial Surgical Excision and Blood Conservation 11.2 Split-Thickness and Full-Thickness Autografting: Mesh Expansion Ratios vs. Sheet Grafts 11.3 Biologic Coverings, Dermal Regeneration Templates (Integra/Novosorb BTM), Allograft, and Xenograft 11.4 Autologous Cell Suspensions (ReCell), Cultured Epithelial Autografts (CEA), and Donor Site Management

12 Chapter 12: Burn Sepsis, Infection Control & Antimicrobial Therapy

12.1 Burn Center Infection Control: Contact Precautions, Hydrotherapy Sanitation, and Environmental Controls 12.2 Differentiating Hypermetabolic SIRS from Burn Sepsis: ABA Consensus Sepsis Criteria 12.3 Common Burn Pathogens (Pseudomonas, MRSA, Acinetobacter, Candida, Aspergillus) and Empiric Coverage 12.4 Invasive Burn Wound Infection: Clinical Signs, Quantitative Biopsy (>10^5 CFU/g), and Histopathological Invasion

13 Chapter 13: Specific Burn Etiologies: Electrical, Chemical & Cold Injuries

13.1 Electrical Burn Injuries: High-Voltage vs. Low-Voltage, Arc/Flash, Cardiac Monitoring, and Deep Muscle Necrosis 13.2 Chemical Injuries: Acids (Coagulation Necrosis), Alkalis (Liquefactive Necrosis), Hydrofluoric Acid (Calcium Gluconate), and Decontamination 13.3 Radiation Burns, Cutaneous Radiation Syndrome, Cold Injuries (Frostbite Triage and Thawing Protocols), and Vasodilator Therapy

14 Chapter 14: Special Burn Populations & Cutaneous Syndromes

14.1 Pediatric Burn Resuscitation (Maintenance Fluids + D5W), Surface Area Dynamics, and Non-Accidental Trauma Screening 14.2 Geriatric Burn Care: Thin Dermis, Altered Fluid Tolerance, Pre-existing Comorbidities, and Mortality Prognostication (Baux Score) 14.3 Burn Injury in Pregnancy: Maternal Physiology, Resuscitation, and Fetal Surveillance 14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing 14.5 Necrotizing Soft Tissue Infections and Friction/Shear Injuries

15 Chapter 15: Rehabilitation, Scar Management & Reconstruction

15.1 Anti-Deformity Positioning, Range-of-Motion Exercises, and Custom Splinting Across Major Joints 15.2 Hypertrophic Scarring Mechanisms, Myofibroblasts, and Vancouver Scar Scale (VSS) Assessment 15.3 Custom Pressure Garments (20-30 mmHg), Silicone Sheeting, Fractional CO2 Laser Resurfacing, and Contracture Release 15.4 Psychosocial Recovery, Post-Traumatic Stress Disorder (PTSD), Body Image Adaptation, Peer Support (Phoenix Society), and School/Work Reintegration 15.5 Discharge Teaching, Transition to Ambulatory Care, and Home Management

16 Chapter 16: Professional Practice, Ethics, Quality & Disaster Triage

16.1 Ethical Dilemmas in Burn Critical Care, Surrogate Decision-Making, Futility, and Palliative / End-of-Life Symptom Management 16.2 Interprofessional Burn Team Roles, Multidisciplinary Rounds, Structured Handoffs, and Patient/Family Advocacy 16.3 Burn Quality Improvement, American Burn Association (ABA) Verification Standards, and National Burn Repository (NBR) Benchmarking 16.4 Diversity, Equity, Inclusion, and Intraprofessional Nursing Development 16.5 Community Outreach, Burn Prevention Education, and Home Safety 16.6 Mass Casualty Burn Disasters, Secondary Triage Schemes (ABA/ABLS Triage Matrix), Surge Capacity, and CBRN/HAZMAT Emergency Response

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support

Key Takeaways Explain This Topic AI

Acute agitation in burn patients requires immediate systematic evaluation to rule out life-threatening physiological triggers—including severe uncontrolled pain, hypoxia, hypercapnia, toxic inhalant encephalopathy (carbon monoxide/cyanide), substance withdrawal, and occult compartment syndrome—before escalating sedative medications.

Clinical practice guidelines advocate for an analgesia-first (analgosedation) approach paired with targeted light sedation (Richmond Agitation-Sedation Scale [RASS] -1 to 0 or Riker Sedation-Agitation Scale [SAS] 3 to 4) to facilitate serial neurological evaluations, ventilator weaning, and early physical mobilization.

Dexmedetomidine (Precedex) is a selective central alpha-2 adrenergic agonist that provides cooperative, conscious sedation with anxiolysis and analgesia without depressing respiratory drive, significantly decreasing ICU delirium rates and bridging patients through extubation.

Propofol provides rapid-onset and rapid-offset GABA-mediated sedation for acute procedural needs and ventilator synchrony, but prolonged infusions (>48 hours at >4–5 mg/kg/hr) require rigorous surveillance for Propofol Infusion Syndrome (PRIS: refractory metabolic acidosis, hyperkalemia, rhabdomyolysis, hepatomegaly, and cardiac collapse).

Circadian rhythm preservation through non-pharmacological ICU sleep hygiene bundles (day-night lighting cycles, clustering nighttime care between 23:00 and 06:00, acoustic alarm attenuation, eye masks, and earplugs) combined with physiological melatonin supplementation restores restorative slow-wave sleep and accelerates recovery.

Last updated: August 2026

9.1 Agitation Management, Targeted Sedation Protocols (RASS/SAS), and Circadian Rhythm Support

Core Knowledge: Agitation in the critically ill burn patient is a high-risk clinical emergency that threatens patient safety, compromises newly grafted surgical sites, accelerates metabolic demand, and predisposes to accidental self-extubation or vascular catheter dislodgement. Modern burn critical care mandates an analgesia-first (analgosedation) paradigm paired with targeted light sedation , prioritizing reversible physiological etiologies before administering sedative-hypnotic pharmacotherapy.

1. Etiological Hierarchy of Acute Agitation in Burn Patients

Agitation must never be reflexively suppressed with sedatives without a thorough, systematic diagnostic evaluation. In the burn ICU, acute motor restlessness, combative behavior, or ventilator dyssynchrony frequently signals life-threatening hypoxemia, acute hypercapnia, or unaddressed somatic pain. DIAGNOSTIC HIERARCHY OF ACUTE AGITATION

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Step 1: Rule Out Immediate Hypoxemia, Hypercapnia & Airway Compromise │
  • │ (ABG, continuous SpO2, EtCO2, endotracheal tube positioning) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Step 2: Assess and Treat Uncontrolled Nociceptive / Neuropathic Pain │
  • │ (CPOT / BPS / NRS; deploy IV opioid / ketamine bolus) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Step 3: Identify Toxic Inhalant Encephalopathy & Metabolic Crises │
  • │ (COHb, Cyanide toxicity, Hypoglycemia, Electrolyte collapse) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Step 4: Screen for Substance Withdrawal Syndromes │
  • │ (Alcohol [CIWA-Ar], Nicotine, Opioid, Benzodiazepine) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Step 5: Alleviate Physical Distress, Urinary Retention & Constriction │
  • │ (Bladder distension, occlusive dressing pressure, ischemia) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Step 6: Modulate Environmental Overstimulation & Sleep Fragmentation │
  • │ (ICU noise >80 dB, constant illumination, sensory overload) │
  • └────────────────────────────────────────────────────────────────────────┘

Primary Etiologies of Burn Agitation:

Uncontrolled Pain: Severe background, procedural, or breakthrough pain is the single most common cause of acute agitation. Burn wounds, donor sites, and tight dressings generate massive nociceptive C-fiber and A-delta signaling.

Respiratory Failure & Hypoxia/Hypercapnia: Upper airway edema, bronchospasm, mucus plugging, acute respiratory distress syndrome (ARDS), or ventilator dyssynchrony trigger profound air hunger and hyperadrenergic agitation.

Toxic Inhalant Toxicity & Encephalopathy: Inhalation injury patients may suffer acute cerebral hypoxia from carbon monoxide (COHb poisoning causing cellular asphyxiation) or hydrogen cyanide (inhibition of cytochrome c oxidase), producing acute encephalopathy and combativeness.

Substance Withdrawal Syndromes:

Alcohol Withdrawal Syndrome (AWS): Tremors, autonomic hyperactivity (hypertension, tachycardia, diaphoresis), hallucinations, and delirium tremens (DTs) typically manifest within 24 to 72 hours post-admission.

Nicotine / Opioid / Polysubstance Withdrawal: Precipitates hyperarousal, nausea, abdominal cramping, and severe restlessness.

Sepsis-Associated Encephalopathy (SAE): Systemic endotoxemia, cytokine release (TNF-α, IL-1β, IL-6), and blood-brain barrier disruption manifest as acute delirium and fluctuating agitation.

Physical Discomfort & Iatrogenic Restraints: Full urinary bladder distension, malpositioned nasogastric tubes, restrictive splints/dressings, and physical wrist restraints amplify anxiety and trigger violent struggling.

2. Objective Sedation Scoring Systems: RASS vs. SAS

Objective sedation scales are essential to standardize titration, prevent iatrogenic over-sedation, and establish a common clinical language across the multidisciplinary burn team. The Society of Critical Care Medicine (SCCM) Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption (PADIS) recommend using either the Richmond Agitation-Sedation Scale (RASS) or the Riker Sedation-Agitation Scale (SAS) . OBJECTIVE SEDATION ASSESSMENT SCALES

  • ┌────────────────────────────────────────┬────────────────────────────────────────┐
  • │ RICHMOND AGITATION-SEDATION (RASS) │ RIKER SEDATION-AGITATION (SAS) │
  • ├────────────────────────────────────────┼────────────────────────────────────────┤
  • │ +4 Combative, violent, danger to self│ 7 Dangerous Agitation (pulls tube) │
  • │ +3 Very agitated, aggressive │ 6 Very Agitated (requires restraint)│
  • │ +2 Agitated, frequent unprompted mvmt│ 5 Agitated (calms with verbal cue) │
  • │ +1 Restless, anxious, apprehensive │ 4 Calm and Cooperative [TARGET] │
  • │ 0 Alert and Calm [TARGET] │ 3 Sedated (difficulty waking) [TGT]│
  • │ -1 Drowsy (eye open >10s to voice) │ 2 Very Sedated (arouses to stimuli)│
  • │ -2 Light sedation (eye open <10s) │ 1 Unarousable (minimal/no response)│
  • │ -3 Moderate sedation (no eye contact)│ │
  • │ -4 Deep sedation (movement to phys) │ │
  • │ -5 Unarousable (no response) │ │
  • └────────────────────────────────────────┴────────────────────────────────────────┘
  • The Light Sedation Mandate in Burn Care

Except in specific clinical circumstances requiring deep sedation (e.g., severe ARDS with neuromuscular blockade, open surgical abdomens, intracranial hypertension, or refractory status epilepticus), the universal clinical target is Light Sedation :

RASS Target: -1 to 0 (Drowsy to Alert and Calm).

SAS Target: 3 to 4 (Sedated to Calm and Cooperative).

Clinical Benefits of Targeted Light Sedation:

Preserves patient ability to interact with the environment and participate in physical therapy.

Allows reliable, serial neurological and delirium assessments (CAM-ICU).

Facilitates spontaneous breathing trials (SBTs) and accelerates successful extubation.

Reduces the duration of mechanical ventilation and ICU length of stay by up to 30–40%.

Decreases the incidence of deep venous thrombosis (DVT) and pressure injuries through spontaneous extremity motion.

3. Sedative Pharmacotherapy in Burn Intensive Care

The SCCM PADIS guidelines strongly endorse an analgesia-first (analgosedation) framework. Opioids and non-opioid analgesics (e.g., IV ketamine, acetaminophen, gabapentinoids) should be optimized to control pain before initiating or up-titrating sedative infusions.

Pharmacological Agent Mechanism of Action Clinical Advantages in Burns Adverse Effects & Nursing Monitoring

Dexmedetomidine (Precedex) Selective central α 2 \alpha_2 α 2 ​ -adrenergic agonist (locus coeruleus) Cooperative "conscious" sedation; anxiolysis; opioid-sparing analgesia; zero respiratory depression ; reduces delirium; facilitates extubation bridging. Bradycardia , peripheral vasodilation/hypotension; hypertension with rapid loading boluses; not suited for deep sedation/paralysis.

Propofol (Diprivan) G A B A A GABA_A G A B A A ​ receptor agonist; NMDA inhibition Rapid onset (1–2 min) and ultra-short offset (3–5 min); potent hypnosis and amnesia; decreases C M R O 2 CMRO_2 CMR O 2 ​ and ICP; excellent for acute ventilator dyssynchrony. Hypotension (systemic vasodilation); respiratory depression; hypertriglyceridemia (1.1 kcal/mL lipid carrier); Propofol Infusion Syndrome (PRIS) .

Midazolam (Versed) Benzodiazepine; positive allosteric G A B A A GABA_A G A B A A ​ modulator Potent anxiolytic, anticonvulsant, and amnestic; water-soluble; preferred for acute alcohol withdrawal or procedural sedation with paralysis. High delirium risk ; prolonged sedation from lipophilic accumulation; active metabolites accumulate in renal impairment; extends ventilator duration.

Lorazepam (Ativan) Benzodiazepine; positive allosteric G A B A A GABA_A G A B A A ​ modulator Intermediate-acting; less hepatic oxidation dependence; drug of choice for established alcohol withdrawal protocols (CIWA-Ar). High delirium risk; propylene glycol solvent toxicity (anion gap metabolic acidosis, acute tubular necrosis, hyperosmolality) during high-dose infusions.

Ketamine Non-competitive NMDA receptor antagonist Dissociative sedation with profound somatic/neuropathic analgesia; maintains airway reflexes and hemodynamics; bronchodilator. Emergence psychomimetic reactions (hallucinations/nightmares); sympathetic stimulation (tachycardia/hypertension); hypersalivation.

4. Propofol Infusion Syndrome (PRIS): Pathophysiology and Surveillance

Propofol Infusion Syndrome (PRIS) is a catastrophic, frequently fatal metabolic crisis triggered by prolonged, high-dose propofol administration. It is especially lethal in burn patients due to their pre-existing hypermetabolism and systemic inflammatory state. PATHOPHYSIOLOGY OF PROPOFOL INFUSION SYNDROME

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Prolonged High-Dose Propofol (>4–5 mg/kg/hr or >67–83 mcg/kg/min >48h) │
  • │ │ │
  • │ ▼ │
  • │ Direct Inhibition of Mitochondrial Electron Transport Chain (Complex IV)│
  • │ & Blockade of Medium/Long-Chain Fatty Acid Entry into Mitochondria │
  • │ │ │
  • │ ▼ │
  • │ Severe Cellular Bioenergetic Starvation & Anaerobic Glycolysis Shift │
  • │ │ │
  • │ ▼ │
  • │ Massive Skeletal / Myocardial Muscle Lysis & Hepatosplenomegaly │
  • │ │ │
  • │ ▼ │
  • │ • Refractory Anion Gap Metabolic Acidosis with Lactic Acidemia │
  • │ • Severe Hyperkalemia & Massive Rhabdomyolysis (Spike in Serum CK) │
  • │ • Acute Renal Pigmentary Failure (Myoglobinuria / Oliguria) │
  • │ • Malignant Cardiac Collapse (Brugada Waveform, Bradycardia, Asystole) │
  • └────────────────────────────────────────────────────────────────────────┘

Clinical Triggers & Safe Practice Benchmarks:

High-Risk Thresholds: Propofol infusion rates > 4 to 5 mg/kg/hr >4\text{ to }5\text{ mg/kg/hr} > 4 to 5 mg/kg/hr (or > 67 to 83 mcg/kg/min >67\text{ to }83\text{ mcg/kg/min} > 67 to 83 mcg/kg/min ) maintained for > 48 hours >48\text{ hours} > 48 hours .

Concomitant Risk Factors: Exogenous catecholamine infusions (epinephrine/norepinephrine), systemic corticosteroid therapy, young age, and severe critical illness.

Mandatory Nursing Surveillance:

Obtain baseline and daily serum triglycerides , creatine kinase (CK) , and arterial blood gases (lactate/base deficit) .

Continuous 12-lead telemetry monitoring for widening QRS complexes, right bundle branch block with ST elevation in leads V1–V3 ( coved Brugada-like ECG pattern ), and refractory bradycardia.

If PRIS is suspected: Immediately terminate the propofol infusion , transition to alternative sedatives (dexmedetomidine, ketamine, or hydromorphone), support hemodynamics (pacing, ECMO if refractory), and initiate continuous renal replacement therapy (CRRT) to clear toxins and correct hyperkalemic acidosis.

5. Sleep Architecture Disruption in the Burn ICU

Sleep deprivation is nearly universal in critically ill burn patients, with polysomnography demonstrating almost complete ablation of slow-wave restorative sleep (Stage N3) and Rapid Eye Movement (REM) sleep . This architectural disruption impairs wound healing, worsens hypermetabolism, escalates pain perception (hyperalgesia), and directly triggers ICU delirium. ETIOLOGIES OF BURN ICU SLEEP FRAGMENTATION

  • ┌────────────────────────────────────────────────────────────────────────┐
  • │ Acoustic Disturbances: Monitor alarms, mechanical ventilators, staff │
  • │ conversations, pneumatic tube deliveries (>65–80 dB; normal <45 dB) │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Optical Disruption: Continuous fluorescent room lighting abverts │
  • │ retinal suprachiasmatic nucleus signaling, abolishing melatonin peak │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Nursing Care Interventions: Vital signs q1h, blood draws, dressing │
  • │ inspections, turns, and medication administration every 30–60 minutes │
  • ├────────────────────────────────────────────────────────────────────────┤
  • │ Physiological & Pharmacological Stressors: Severe background burn │
  • │ pain, pruritus, systemic hypermetabolic catecholamine storm, opioids │
  • └────────────────────────────────────────────────────────────────────────┘

Multicomponent Sleep Hygiene Bundle (Circadian Protocol):

To restore circadian entrainment and promote endogenous melatonin secretion, burn units implement standardized non-pharmacological sleep bundles:

Circadian Lighting Regulation:

Daytime (07:00–21:00): Open window shades, maximize exposure to natural sunlight, maintain bright ambient room lighting ( > 300 lux >300\text{ lux} > 300 lux ) to reinforce wakefulness.

Nighttime (22:00–06:00): Dim room lights ( < 30 lux <30\text{ lux} < 30 lux ), turn off overhead spotlights, minimize computer terminal glare.

Clustering Nighttime Nursing Care:

Consolidate routine blood sampling, linen changes, dressing changes, and non-emergent medication administration during daytime hours.

Establish a protected "Quiet Time" window (23:00 to 05:30) where patient entries are limited to strictly essential critical checks.

Acoustic & Sensory Attenuation:

Maintain ICU sound levels < 45 dB <45\text{ dB} < 45 dB at night by lowering telemetry and infusion pump alarm volumes to safe minimum thresholds.

Provide high-attenuation foam earplugs and contoured eye sleep masks to every conscious patient.

Deploy continuous low-frequency white noise or calming ambient music.

Pharmacological Circadian Promotion:

Exogenous Melatonin: Administer 3 to 10 mg PO/NG at 21:00 to induce physiological sleep phase advancement and provide antioxidant cytoprotection.

Melatonin Receptor Agonists: Ramelteon (8 mg PO) selectively binds MT1 and MT2 receptors without hypnotic hangover or respiratory depression.

Avoid Deliriogenic Nighttime Sedation: Strictly avoid routine nighttime benzodiazepines (lorazepam/temazepam) or antihistamines (diphenhydramine), as they extinguish REM architecture and worsen confusion.